Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
672 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Regulatory
66 approval records across 2 jurisdictions, including tumor-agnostic approvals.
| Drug | Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|---|
| Trastuzumab Deruxtecan | US FDA | Tumor-agnostic | HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated | approved | Dec 20, 2019 | openfda |
| Trastuzumab Deruxtecan | US FDA | Tumor-agnostic | HER2-Positive Locally Advanced or Metastatic Gastric Cancer as monotherapy for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. • HER2-Positive (IHC 3+) Unresectable or Metastatic Solid Tumors as monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options* • * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )accelerated | approved | Dec 20, 2019 | openfda |
Data updated yesterdaySource updated unknown
Curated evidence
Counts of CIViC evidence items mentioning each therapy for this entity or its descendants. Presence here is not an approval.
| Therapy | Evidence items (count) | Sensitivity / response | Resistance |
|---|---|---|---|
| Erdafitinib | 18 | 16 | 2 |
| Chemotherapy | 12 | 12 | 0 |
| Everolimus | 11 | 9 | 2 |
| Lapatinib | 6 | 6 | 0 |
| Pazopanib | 6 | 5 | 1 |
| Sunitinib | 5 | 2 | 2 |
| MTOR Inhibitor | 4 | 4 | 0 |
| Anti-VEGF Monoclonal Antibody | 3 | 2 | 1 |
| Futibatinib | 3 | 2 | 1 |
| Infigratinib | 3 | 3 | 0 |
| Palbociclib | 3 | 3 | 0 |
| PD173074 | 3 | 3 | 0 |
| Temsirolimus |
Regulatory status is jurisdiction-specific and changes over time. This page is not treatment guidance.
| 3 |
| 3 |
| 0 |
| Atezolizumab | 2 | 2 | 0 |
| Bevacizumab | 2 | 2 | 0 |
| Cisplatin | 2 | 1 | 0 |
| Dovitinib | 2 | 2 | 0 |
| Erlotinib | 2 | 2 | 0 |
| Nivolumab | 2 | 2 | 0 |
| Olaparib | 2 | 2 | 0 |
| Sorafenib | 2 | 1 | 1 |
| Abexinostat | 1 | 1 | 0 |
| Afatinib | 1 | 1 | 0 |
| Akt Inhibitor MK2206 | 1 | 1 | 0 |
| Anti-PD1 Monoclonal Antibody | 1 | 1 | 0 |
| Anti-PD-L1 Monoclonal Antibody | 1 | 1 | 0 |
| ATR Inhibitor | 1 | 1 | 0 |
| AZD-4547 | 1 | 1 | 0 |
| B-Raf/VEGFR-2 Inhibitor RAF265 | 1 | 1 | 0 |
| Checkpoint Kinase Inhibitor AZD7762 | 1 | 1 | 0 |
| CTLA-4 Inhibitor | 1 | 1 | 0 |
| Durvalumab | 1 | 1 | 0 |
| Fexagratinib | 1 | 1 | 0 |
| Foretinib | 1 | 1 | 0 |
| Gefitinib | 1 | 1 | 0 |
| Gemcitabine | 1 | 0 | 0 |
| Immune Checkpoint Inhibitor | 1 | 0 | 1 |
| Immunotherapy | 1 | 1 | 0 |
| Ipilimumab | 1 | 1 | 0 |
| Irinotecan | 1 | 1 | 0 |
| JQ1 | 1 | 1 | 0 |
| Metformin | 1 | 1 | 0 |
| Niraparib | 1 | 1 | 0 |
| Paclitaxel | 1 | 0 | 0 |
| Pembrolizumab | 1 | 1 | 0 |
| Pemetrexed | 1 | 1 | 0 |
| Pertuzumab | 1 | 1 | 0 |
| PI3Kbeta Inhibitor AZD8186 | 1 | 1 | 0 |
| Platinum Compound | 1 | 1 | 0 |
| R3Mab | 1 | 0 | 1 |
| Sirolimus | 1 | 1 | 0 |
| TGX221 | 1 | 1 | 0 |
| Tipifarnib | 1 | 1 | 0 |
| Trametinib | 1 | 1 | 0 |
| Trastuzumab | 1 | 1 | 0 |
| Tyrosine Kinase Inhibitor SU5402 | 1 | 1 | 0 |
| UO126 | 1 | 1 | 0 |
| Vandetanib | 1 | 1 | 0 |
Curated Items are counted regardless of level or direction; see the evidence tab for the detail.